What has senescence got to do with cancer?

Cancer Cell. 2005 Jun;7(6):505-12. doi: 10.1016/j.ccr.2005.05.025.


Cancer therapeutics are primarily thought to work by inducing apoptosis in tumor cells. However, various tumor suppressors and oncogenes have been shown to regulate senescence in normal cells, and senescence bypass appears to be an important step in the development of cancer. Cellular senescence limits the replicative capacity of cells, thus preventing the proliferation of cells that are at different stages of malignancy. A recent body of evidence suggests that induction of senescence can be exploited as a basis for cancer therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Cellular Senescence / drug effects
  • Cellular Senescence / physiology*
  • Humans
  • Models, Biological
  • Neoplasm Proteins / physiology
  • Neoplasms / drug therapy*
  • Neoplasms / physiopathology
  • Nuclear Proteins / physiology
  • Promyelocytic Leukemia Protein
  • Retinoblastoma Protein / physiology
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Telomere / physiology
  • Transcription Factors / physiology
  • Tumor Suppressor Protein p14ARF / physiology
  • Tumor Suppressor Protein p53 / physiology
  • Tumor Suppressor Proteins / physiology


  • Antineoplastic Agents
  • Neoplasm Proteins
  • Nuclear Proteins
  • Promyelocytic Leukemia Protein
  • Retinoblastoma Protein
  • Transcription Factors
  • Tumor Suppressor Protein p14ARF
  • Tumor Suppressor Protein p53
  • Tumor Suppressor Proteins
  • PML protein, human